AI-designed medicines

Drugs whose targets and molecules came from AI, proven in the clinic.

Facts

Lane: Science and health
Wave: 4 of 12 (build order, not a date)
Needs: 10 boxes all the way back through hard links
Unlocks: 1 boxes downstream through hard links
Leverage: 0.2 points · stands in the way of 1 of 53 stages · rank 47 of 57
Cluster: Science and medicine
When: Sourced forecast: 2029 to 2031

Evidence as of October 2026

Insilico’s rentosertib for lung fibrosis showed results in phase IIa and moved into phase III. Isomorphic Labs pushed its first trials from 2025 to the end of 2026.

Watch
AI-designed drugs passing phase III. The first readout is expected around 2029.

Timeline note
Insilico’s phase III: initial results expected by December 2029, a possible approval filing in 2030.

01Insilico Medicine launches phase III trial for AI-developed drug

Around it

Needs · 3

Protein structure and designcapability · Built today
Lab automationcapability · Emerging
Clinical validationcapability · Emerging

Unlocks · 1

AI-native medicinestage · Speculative

Loops and off-ramps

Capex pullbackoff-ramp · cut off
Taiwan chip disruptionoff-ramp · cut off
Power shortfalloff-ramp · cut off
Training data ruled outoff-ramp · slowed

Openings researchers' judgement, October 2026 scouting

Startup room 28/100 · rank 115 of 124 Research room 33/100 · rank 112 of 124

Crowding5 Lab overlap5 Small-team fit2 Buyer today4 Research openness3

Depth: light
Players: Isomorphic Labs ($2.1bn B); Insilico; Xaira; 75+ AI-discovered molecules in trials (BCG)
Wedge: Evidence on whether AI raises Phase 2 efficacy, not just speed; no small-team product wedge supported. research